Expression of ERCC1, Bcl-2, MT and their clinical significance in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy
The aim of this study was to determine the prognostic value of expression of Excision Repair Cross-complementation Group 1 (ERCC1), B cell lymphoma/lewkmia-2 (Bcl-2) and metallothionein (MT) by immunohistochemically staining tumor specimens from 78 patients with advanced non-small-cell lung cance...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Articulo |
| Lenguaje: | Inglés |
| Publicado: |
2009
|
| Materias: | |
| Acceso en línea: | http://sedici.unlp.edu.ar/handle/10915/7842 http://www.latamjpharm.org/trabajos/28/6/LAJOP_28_6_1_4_1ER34O4VWY.pdf |
| Aporte de: |
| Sumario: | The aim of this study was to determine the prognostic value of expression of Excision Repair
Cross-complementation Group 1 (ERCC1), B cell lymphoma/lewkmia-2 (Bcl-2) and metallothionein (MT)
by immunohistochemically staining tumor specimens from 78 patients with advanced non-small-cell lung
cancer (NSCLC) treated with cisplatin-based chemotherapy. The result showed that positive expression of
ERCC1 was associated both with short survival (10.45 months vs. 14.38 months, log-rank p = 0.003) and
poor response to cisplatin-based chemotherapy (p = 0.003) when compared with negative group. But expression
of Bcl-2 and MT was not associated with response to chemotherapy and survival. Multivariate
analysis confirmed that expression of ERCC1 was an independent variable related to overall survival (p =
0.013). These data support the role of RECC1 expression as a candidate predictor for the survival of patients
with advanced NSCLC treated with cisplatin-based chemotherapy. |
|---|